Clive A Prestidge
Overview
Explore the profile of Clive A Prestidge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
209
Citations
1732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ariaee A, Koentgen S, Wardill H, Hold G, Prestidge C, Armstrong H, et al.
eGastroenterology
. 2025 Feb;
2(2):e100055.
PMID: 39944472
Inflammatory bowel disease (IBD) is characterised by chronic inflammation in the gastrointestinal tract, with unclear aetiology but with known factors contributing to the disease, including genetics, immune responses, environmental factors...
2.
Mahboob M, Subramaniam S, Tait J, Grace J, Elliott A, Floyd H, et al.
J Mater Chem B
. 2025 Jan;
13(8):2776-2795.
PMID: 39869058
Infections caused by fungal pathogens are a global health problem, and have created an urgent need for new antimicrobial strategies. This report details the synthesis of lipidated 2-vinyl-4,4-dimethyl-5-oxazolone (VDM) oligomers...
3.
Wright L, Wignall A, Subramaniam S, Schultz H, Joyce P, Prestidge C
Int J Pharm
. 2025 Jan;
670:125179.
PMID: 39778728
Decreased saliva production due to salivary gland damage can result in difficulty speaking and swallowing, significantly reducing quality of life for head and neck cancer patients receiving radiotherapy. It is...
4.
Ariaee A, Wardill H, Wignall A, Prestidge C, Joyce P
Foods
. 2025 Jan;
13(24.
PMID: 39767129
In the original publication [...].
5.
Feizi S, Awad M, Ramezanpour M, Cooksley C, Murphy W, Prestidge C, et al.
ACS Appl Mater Interfaces
. 2024 Dec;
16(51):70274-70283.
PMID: 39660476
Nontuberculous mycobacteria (NTM) are among the recalcitrant bacterial strains that cause difficult-to-treat infections for patients with chronic underlying pulmonary conditions. The bacteria's intrinsic resistance to various antibiotics and their ability...
6.
Hosseini-Kharat M, Bremmell K, Grubor-Bauk B, Prestidge C
J Control Release
. 2024 Dec;
378:170-194.
PMID: 39647508
DNA-based therapies are often limited by challenges such as stability, long-term integration, low transfection efficiency, and insufficient targeted DNA delivery. This review focuses on recent progress in the design of...
7.
Taheri A, Almasri R, Wignall A, Schultz H, Elz A, Ariaee A, et al.
Drug Deliv Transl Res
. 2024 Nov;
PMID: 39614037
Abiraterone acetate, a prodrug of abiraterone, is an effective antiandrogen for treating metastatic prostate cancer. However, its poor aqueous solubility restricts oral bioavailability to under 10% in fasted conditions. Additionally,...
8.
King J, Chen K, Evans C, Norret M, Almasri R, Pavlos N, et al.
Chem Sci
. 2024 Sep;
PMID: 39246363
Antisense oligonucleotides (ASOs) are a well-established therapeutic modality based on RNA interference, but low cellular uptake, limited ability to direct ASO trafficking, and a range of intracellular barriers to successful...
9.
Joyce P, Allen C, Alonso M, Ashford M, Bradbury M, Germain M, et al.
Nat Nanotechnol
. 2024 Sep;
19(11):1597-1611.
PMID: 39242807
Nanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding...
10.
Meola T, Kamath S, Elz A, Prestidge C, Wignall A, Joyce P
Eur J Pharm Biopharm
. 2024 Aug;
203:114453.
PMID: 39134099
Increasing attention is being afforded to understanding the bidirectional relationship that exists between oral drugs and the gut microbiota. Often overlooked, however, is the impact that pharmaceutical excipients exert on...